$SCNX

Scienture Holdings (SCNX) announced that its Arbli™ (losartan potassium) Oral Suspension has been added to the formularies of three leading U.S. pediatric medical centers. Arbli™ addresses a $219 million U.S. losartan market, with 72 million prescriptions annually. The company reported increasing wholesale orders and sees significant growth potential, especially in pediatric care.

Scienture Holdings, Inc. (NASDAQ: SCNX) announced a 1-for-25 reverse stock split, effective October 5, 2026. The company aims to meet Nasdaq's minimum bid price requirement and free up shares for future issuance. Outstanding shares will reduce from 41,064,146 to approximately 1,642,565. The stock will continue trading under the symbol SCNX.

Scienture Holdings, Inc. (SCNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company’s Growing Commercial Revenue Base Q2 2026 Operat

Scienture Holdings (NASDAQ: SCNX) reported Q2 2026 results: revenue rose about 510% sequentially to $343,639 from $56,325 in Q1. Q2 gross margin was about 97.7%. Operating loss improved about 48% to ~$2.7M and net loss narrowed about 58% to ~$2.8M. The company began commercial launch of REZENOPY and cited USPTO patent grants and expanded payer coverage.

Scienture (NASDAQ:SCNX) says it has commercially launched REZENOPY, a 10 mg naloxone hydrochloride nasal spray, after fulfilling initial U.S. wholesaler purchase orders and starting nationwide distribution. The company cites IQVIA data for a $143 million U.S. naloxone market (9.8 million units) and says payer coverage could exceed 100 million lives via GPO access to 5,000+ facilities. No revenue guidance was provided.

Scienture Holdings (NASDAQ:SCNX) shares rose about 21% pre-market to $0.4046 after the company said it completed manufacturing of commercial launch inventory for REZENOPY (naloxone HCl) 10 mg nasal spray. Shipments to U.S. wholesalers are expected later this month, with retail availability in August. SCNX closed Thursday at $0.33.

Scienture Holdings (SCNX) said it completed manufacturing commercial launch inventory for REZENOPY naloxone nasal spray 10 mg and will start shipments to U.S. wholesalers in July, with broad availability expected in August. The company cited IQVIA data valuing the U.S. naloxone market at about $144 million annually and said payer access could cover over 100 million lives.

Scienture Holdings (NASDAQ: SCNX) said the U.S. Patent and Trademark Office granted U.S. Patent No. 12,622,903 B2 covering REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective May 12, 2026 and expiring Feb. 5, 2041. The patent was issued to Summit Biosciences, a subsidiary of Kindeva. Scienture’s subsidiary has exclusive U.S. commercialization rights; REZENOPY™ was FDA-approved April 19, 2024. IQVIA data cited: ~$141M annual U.S. naloxone sales and 9.4M units (MAT Jan 2026).

Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to ...

On Thursday, Scienture Holdings, Inc. ( NASDAQ:SCNX ) reported financial results for the third quarter. Net revenue increased from approximately $65 thousand to $590 thousand, while gross profit increased from roughly $4 thousand to $575 thousand.